Sinovac setback
China's big vaccine-export hope, Sinovac's CoronaVac, just suffered a huge blow: it's only 50.4% effective, according to the results of its first large-scale, late-stage trial. The trial was conducted by Brazil's Butantan Institute, which claimed last week that the efficacy rate was 78%. Now, it says that figure left out "very mild" cases that did not require medical assistance. CNBC
China's big vaccine-export hope, Sinovac's CoronaVac, just suffered a huge blow: it's only 50.4% effective, according to the results of its first large-scale, late-stage trial. The trial was conducted by Brazil's Butantan Institute, which claimed last week that the efficacy rate was 78%. Now, it says that figure left out "very mild" cases that did not require medical assistance. CNBC